Zacks Investment Research
24 Sept 2026, 17:51 UTC · 1h ago
Verdict
Headline takes no side. We score EXEL −0.60 across two claims — strongly bearish.
−0.60strongly bearish
More negative than 79% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 0 new · 2 priced in
The FDA extended the target action date for zanzalintinib's NDA in metastatic colorectal cancer by three months to March 3, 2027.
Priced inannounced on Sept. 10, 2026
So whatThe shift from Dec 2026 to March 2027 pushes potential peak revenue recognition into the next fiscal year.
More negative than 87% of claims this week
The FDA classified Exelixis' submission of updated safety and efficacy data for zanzalintinib as a major amendment.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Priced inannounced on Sept. 10, 2026
More negative than 71% of claims this week
Which stocks this story touches
More negative than 79% of ticker scores this week
The FDA extended the review period for its drug zanzalintinib, causing a delay in regulatory decision and a drop in share price.
Near neutral — 92% of ticker scores this week are stronger
Mentioned as a collaborator for a planned study, with no material impact described.
Near neutral — 92% of ticker scores this week are stronger
Mentioned as a collaborator in the drug study, but not meaningfully impacted by the review extension.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
More positive than 56% of relationship scores this week
[mutual] Exelixis is developing a drug candidate in combination with Roche's Tecentriq.
+2.0%
Price is moving against the score
$57.87 vs $56.73 close before publication (Sep 23) · not market-adjusted
EXEL chart →
